Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

A study indicates ALS Functional Rating Scale-Revised self-assessments using a smartphone app were as reliable as those done ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a clinical trial nearly eight years ago, her symptoms have not gotten any worse.

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. | As other gene editing programs ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients have with therapies from Alnylam and Novo Nordisk.

Best known would be Loudon Wainwright III, a singer-songwriter whose music ranges from wry to intimate and who is now in his ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Voyager Therapeutics ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.

The state Legislature plans to meet in joint session Wednesday to take up Gov. Mike Dunleavy’s Executive Order creating a ...